ClinicalTrials.gov
public full text
Public Domain
Safety of an Infant Formula With Hydrolysed Protein in Term Infants
A multi-centre, randomised, double-blind, parallel-group, controlled, prospective, non-inferiority intervention clinical trial is performed to assess the safety and suitability of an infant formula manufactured from extensively hydrolysed protein by showing normal growth of healthy term infants during the first 120 days of life with an optional follow up until 180 days of life.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110#804073
- Life With Phenylketonuria. Adult Neurological Outcome of PCU Screened Patients From 1971 to 2002.#866707
- Gastric Residual Volumes in Infants Fed at 4 and 6 Hours Prior to General Anaesthesia#1033091
- Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia#980570
- Joint FAO/WHO Expert Meeting on Microbiological Risk Assessment (JEMRA) on microbiological risk assessment on powdered formulae for infants and young children. List of Experts#180453
Record · ID 908932
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive